Drug overdoses have declined for a third straight year, according to preliminary data released by the CDC on May 13. 1 The ...

Formal adoption of PMOS replaces a cyst-centric label with terminology capturing endocrine, metabolic, and ovarian dysfunction that drives infertility, menstrual irregularity, and long-term ...

Accelerated approval covers post–BTK inhibitor relapsed/refractory MCL, making sonrotoclax the only BCL2 inhibitor specifically approved for this indication. Independent Lugano-assessed efficacy in ...

Regulatory clearance creates an at-home, 28-day cycle option using oral decitabine/cedazuridine on days 1–5 plus venetoclax 400 mg daily after a ramp-up cycle. Efficacy signals in ASCERTAIN-V included ...

An international consortium of pediatric oncology experts has published consensus guidelines on radiation treatment for children with metastatic rhabdomyosarcoma (RMS), offering site-specific ...

Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on ...

Single adequate and well-controlled trial plus confirmatory evidence became the default approval paradigm, formalizing a trend already common for first-in-class oncology and rare-disease products.

New real-world evidence presented at PQA 2026 exposes the blind spots in how medication adherence is measured, monitored, and ...

RBM20 truncating variants ( RBM20 tvs) appear to contribute to arrhythmogenic dilated cardiomyopathy (DCM) but with ...

Food insecurity identification modeling for Medicare can establish a reliable method of prioritizing members at risk of food ...

In part 2 of her interview with The American Journal of Managed Care®, Deborah Doroshow, MD, PhD, assistant professor of ...

Women with endometriosis have an elevated risk of developing epithelial ovarian cancer, but, when they do develop it, they ...